



**XTL Biopharmaceuticals Announces Corporate Presentations to be Held Today,
Monday, November 6, 2006**

-- Rodman & Renshaw 8th Annual Healthcare Conference --

-- CIBC World Markets 17th Annual Healthcare Conference --

For Immediate Release

NEW YORK, NEW YORK, November 6, 2006 – XTL Biopharmaceuticals Ltd. (NASDAQ: XTLB; LSE: XTL; TASE: XTL) announced today that Ron Bentsur, the Company's Chief Executive Officer, is scheduled to present at the Rodman & Renshaw 8th Annual Healthcare Conference and the CIBC World Markets 17th Annual Healthcare Conference. Both presentations will be held today, as follows:

Rodman & Renshaw 8th Annual Healthcare Conference – 10:15 am EST at the New York Palace Hotel in New York City. A live webcast of Mr. Bentsur's presentation will be available at <http://www.wsw.com/webcast/rrshq10/xtl.ln/>. An archived version of the webcast will be available following the conclusion of the live presentation.

CIBC World Markets 17th Annual Healthcare Conference – 12:55 pm EST at the Waldorf Astoria Hotel in New York City. A live webcast of Mr. Bentsur's presentation will be available at <http://www.veracast.com/webcasts/cibcwm/healthcare06/54109276.cfm>. An archived version of the webcast will be available following the conclusion of the live presentation.

ABOUT XTL BIOPHARMACEUTICALS LTD.

XTL Biopharmaceuticals Ltd. ("XTL") is engaged in the acquisition, development and commercialization of therapeutics for the treatment of infectious diseases, with a focus on hepatitis C. XTL is developing XTL-2125 - a small molecule, non-nucleoside inhibitor of the hepatitis C virus polymerase. XTL-2125 is currently in a Phase 1 clinical trial in patients with chronic hepatitis C. XTL is also developing XTL-6865 - a combination of two monoclonal antibodies against the hepatitis C virus - presently in Phase 1 clinical trials in patients with chronic hepatitis C. XTL's hepatitis C pipeline also includes several families of pre-clinical hepatitis C small molecule inhibitors. XTL also has an active in-licensing and acquisition program designed to identify and acquire additional drug candidates. XTL is publicly traded on the NASDAQ, London, and Tel-Aviv Stock Exchanges (NASDAQ: XTLB; LSE: XTL; TASE: XTL).

Contact:

Ron Bentsur, Chief Executive Officer
Tel: +1-(212)-531-5960